The safety of biological pharmacotherapy for the treatment of ulcerative colitis

References

• Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005;128:1805–1811. ​
   PubMed Web of Science ®Google Scholar
• Tursi A, Elisei W, Brandimarte G, et al. Safety and effectiveness of infliximab for inflammatory bowel diseases in clinical practice. Eur Rev Med Pharmacol Sci. 2010 Jan;14(1):47–55.
   PubMed Web of Science ®Google Scholar
• Lopez A, Ford AC, Colombel JF, et al. Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: meta-analysis of placebo-controlled trials. Dig Liver Dis. 2015;47:356–364.
   PubMedGoogle Scholar
• Danese S, Panes J. Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases. Gastroenterology. 2014;147:981–989.
   PubMed Web of Science ®Google Scholar
• Danese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Ann Intern Med 2014;160:704–711
   PubMed Web of Science ®Google Scholar
• Danese S, Fiorino G, Reinisch W. Review article: causative factors and the clinical management of patients with Crohn’s disease who lose response to anti-TNF-alpha therapy. Aliment Pharmacol Ther. 2011;34:1–10.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Ghosh S, et al. Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: data from ULTRA 1, 2, and 3. Am J Gastroenterol. 2014;109:1771–1780.
   PubMed Web of Science ®Google Scholar
• Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011;60:780–787.
   PubMed Web of Science ®Google Scholar
• Reinisch W, Sandborn WJ, Panaccione R, et al. 52-week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants. Inflamm Bowel Dis. 2013;19:1700–1709.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142(257–65):e1–3.
   Google Scholar
• Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146:85–95. quiz e14-5
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146(96–109):e1.
   Google Scholar
• Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117:244–279.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn’s disease: more than 5 years of follow-up in the TREAT registry. Am J Gastroenterol. 2012;107:1409–1422.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl Med. 2005 Dec 8;353(23):2462–2476.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Rutgeerts P, Sandborn WJ, et al. A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol. 2012 Jul;107(7):1051–1063.
   PubMed Web of Science ®Google Scholar
• Bonovas S, Fiorino G, Allocca M, et al. Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol. 2016 Oct;14(10):1385–1397.
   PubMed Web of Science ®Google Scholar
• Pillet S, Jarlot C, Courault M, et al. Infliximab does not worsen outcomes during flare-ups associated with cytomegalovirus infection in patients with ulcerative colitis. Inflamm Bowel Dis. 2015 Jul;21(7):1580–1586.
   PubMed Web of Science ®Google Scholar
• Rahier JF, Magro F, Abreu C, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014;8:443–468.
   PubMed Web of Science ®Google Scholar
• Sen S, Peltz C, Jordan K, et al. Infliximab-induced nonspecific interstitial pneumonia. Am J Med Sci. 2012;344:75–78.
   PubMed Web of Science ®Google Scholar
• Reid JD, Bressler B, English J. A case of adalimumab-induced pneumonitis in a 45-year-old man with Crohn’s disease. Can Respir J. 2011;18:262–264.
   PubMed Web of Science ®Google Scholar
• Godet PG, Cowie R, Woodman RC, et al. Pulmonary function abnormalities in patients with ulcerative colitis. Am J Gastroenterol. 1997 Jul;92(7):1154–1156.
   PubMed Web of Science ®Google Scholar
• Lossos A, River Y, Eliakim A, et al. Neurologic aspects of inflammatory bowel disease. Neurology. 1995;45:416–421.
   PubMed Web of Science ®Google Scholar
• Sassi SB, Kallel L, Ben Romdhane S, et al. Peripheral neuropathy in inflammatory bowel disease patients: a prospective cohort study. Scand J Gastroenterol. 2009;44:1268–1269.
   PubMed Web of Science ®Google Scholar
• Naranjo CA, Busto U, Sellars EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–245.
   PubMed Web of Science ®Google Scholar
• Deepak P, Stobaugh DJ, Sherid M, et al. Neurological events with tumour necrosis factor alpha inhibitors reported to the food and drug administration adverse event reporting system. Aliment Pharmacol Ther. 2013 Aug;38(4):388–396.
   PubMed Web of Science ®Google Scholar
• Alexandre B, Vandermeeren Y, Dewit O, et al. ECCO CONFER investigators. optic neuritis associated or not with tnf antagonists in patients with inflammatory bowel disease. J Crohns Colitis. 2016 May;10(5):541–548.
   PubMed Web of Science ®Google Scholar
• Harbord M, Annese V, Vavricka SR, et al. European crohn’s and colitis organisation. the first european evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2016 Mar;10(3):239–254.
   PubMed Web of Science ®Google Scholar
• Fiorino G, Danese S, Pariente B, et al. Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-α agents. Autoimmun Rev. 2014 Jan;13(1):15–19.
   PubMed Web of Science ®Google Scholar
• Pugliese D, Guidi L, Ferraro PM, et al. Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study. Aliment Pharmacol Ther. 2015 Oct;42(7):880–888.
   PubMed Web of Science ®Google Scholar
• Fréling E, Baumann C, Cuny JF, et al. Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience. Am J Gastroenterol. 2015 Aug;110(8):1186–1196.
   PubMed Web of Science ®Google Scholar
• Herszényi L, Barabás L, Miheller P, et al. Colorectal cancer in patients with Inflammatory bowel disease: the true impact of the risk. Digestive Disease. 2015;33:52–57.
   PubMed Web of Science ®Google Scholar
• Shaukat A, Virnig DJ, Salfiti NI, et al. Is inflammatory bowel disease an important risk factor among older persons with colorectal cancer in the united states? a population-based case–control study. Dig Dis Sci. 2011;56:2378.
   PubMed Web of Science ®Google Scholar
• Cheddani H, Dauchet L, Gislum M, et al. 557 cancer in elderly-onset inflammatory bowel disease: a population-based study. Gastroenterology. 2014;5:S–101.
   Google Scholar
• Lutgens MW, van Oijen MG, van der Heijden GJ, et al. Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Ibd. 2013;19:789–799.
   PubMed Web of Science ®Google Scholar
• Mazzola P, Radhi S, Mirandola L, et al. Aging, cancer, and cancer vaccines. Immun Ageing. 2012 Apr 17;9(1):4.
   PubMed Web of Science ®Google Scholar
• Annese V, Beaugerie L, Egan L, et al. European evidence-based consensus: inflammatory bowel disease and malignancies. J Crohns Colitis. 2015 Nov;9(11):945–965.
   PubMed Web of Science ®Google Scholar
• Annese V, Daperno M, Rutter MD, et al. European Crohn’s and colitis organisation. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis. 2013 Dec;7(12):982–1018.
   PubMed Web of Science ®Google Scholar
• Farraye FA, Odze RD, Eaden J, et al. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010;138:738–745.
   PubMed Web of Science ®Google Scholar
• Long MD, Martin CF, Pipkin CA, et al. Risk of melanoma and non-melanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology. 2012;143(390–399):e1.
   Google Scholar
• Kappelman MD, Farkas DK, Long MD, et al. Risk of cancer in patients with inflammatory bowel diseases: a nationwide population-based cohort study with 30 years of follow-up evaluation. Clin Gastroenterol Hepatol. 2014;12(265–73):e1.
   Google Scholar
• Fidder H, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut. 2009;58:501–508.
   PubMed Web of Science ®Google Scholar
• Dixon WG, Watson KD, Lunt M, et al. British society for rheumatology biologics register control centre consortium; british society for rheumatology biologics register.influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British society for rheumatology biologics register. Arthritis Care Res. 2010;62:755–756.
   PubMed Web of Science ®Google Scholar
• Axelrad J, Bernheim O, Colombel JF, et al. New york crohn’s and colitis organization.risk of new or recurrent cancer in patients with inflammatory bowel disease and previous cancer exposed to immunosuppressive and anti-tumor necrosis factor agents.Clin Gastroenterol Hepatol. 2016 Jan;14(1):58–64. Epub 2015 Aug 3 DOI:10.1016/j.cgh.2015.07.037
   PubMed Web of Science ®Google Scholar
• Wheat CL, Clark-Snustad K, Devine B, et al. Worldwide incidence of colorectal cancer, leukemia, and lymphoma in inflammatory bowel disease: an updated systematic review and meta-analysis. Gastroenterol Res Pract. 2016;2016:1632439.
   PubMed Web of Science ®Google Scholar
• Deepak P, Sifuentes H, Sherid M, et al. T-cell non Hodgkin’s lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-alpha) inhibitors: results of the REFURBISH study. Am J Gastroenterol. 2013 Jan;108(1):99–105.
   PubMed Web of Science ®Google Scholar
• Herrinton LJ, Liu L, Weng X, et al. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am J Gastroenterol. 2011 Dec;106(12):2146–2153.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699–710.
   PubMed Web of Science ®Google Scholar
• Wyant T, Leach T, Sankoh S, et al. Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results. Gut. 2015;64:77–83.
   PubMed Web of Science ®Google Scholar
• European Medicine Agency Summary of the risk management plan (RMP) for Entyvio (vedolizumab) 2014. [cited 2016 Apr 10]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Risk-management plan_summary/human/002782/WC500163289.pdf
   Google Scholar
• Colombel JF, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut. 2016 Feb 18;0:1–13. doi:10.1136/gutjnl-2015-311079. ​
   Web of Science ®Google Scholar
• Baumgart DC, Bokemeyer B, Drabik A, et al. Vedolizumab induction therapy for inflammatory bowel disease in clinical practice – a nationwide consecutive German cohort study. Aliment Pharmacol Ther. 2016 May;43(10):1090–1102.
   PubMed Web of Science ®Google Scholar
• Vivio EE, Kanuri N, Gilbertsen JJ, et al. Vedolizumab effectiveness and safety over the first year of use in an IBD clinical practice. J Crohns Colitis. 2016 Apr;10(4):402–409.
   PubMed Web of Science ®Google Scholar
• European Medicine Agency Remicade. EPAR Summary for the Public 2009. [cited 2016 Apr 10]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Summary_for_the_public/human/000240/WC500050883.pdf
   Google Scholar
• European Medicine Agency Inflectra. EPAR Summary for the Public 2013. [cited 2016 Apr 10]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Summary_for_the_public/human/002778/WC500151491.pdf
   Google Scholar
• European Medicine Agency Remsima. EPAR Summary for the Public 2013. [cited 2016 Apr 10]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002576/WC500150872.pdf
   Google Scholar
• European Medicine Agency Humira. EPAR Summary for the Public 2009. [cited 2016 Apr 10]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Summary_for_the_public/human/000481/WC500050865.pdf
   Google Scholar
• European Medicine Agency Simponi. EPAR Summary for the Public 2009. [cited 2016 Apr 10]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Summary_for_the_public/human/000992/WC500052370.pdf
   Google Scholar
• European Medicine Agency Entyvio. EPAR Summary for the Public 2014. [cited 2016 Apr 10]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Summary_for_the_public/human/002782/WC500168532.pdf
   Google Scholar
• van der Woude CJ, Ardizzone S, Bengtson MB, et al. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohns Colitis. 2015;9:107–124.
   PubMed Web of Science ®Google Scholar
• van de Casteele N, Ferrante M, van Assche G, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology. 2015;148(1320–9):e3.
   Google Scholar